Terminated PHASE2 NCT01408407

Alkagin Paste in the Prevention of Radiation Dermatitis

A Phase II Study Designed to Evaluate the Value of Alkagin Paste in the Prevention of Radiation Dermatitis for Patients Undergoing External Radiation Therapy

Sponsor: Avario Healthcare Inc.

Conditions Anus Neoplasms Rectal Neoplasms Urogenital Neoplasms

Interventions Alkagin paste Aveeno cream

Updated 5 times since 2017 Last updated: May 22, 2015 Started: Dec 31, 2011 Primary completion: May 31, 2014

This PHASE2 trial investigates Anus Neoplasms and Rectal Neoplasms and is currently terminated or withdrawn. Avario Healthcare Inc. leads this study, which shows 5 recorded versions since 2011 — indicating limited longitudinal coverage. As an oncology study, it adds to the longitudinal record of treatment development for this indication.

Status Flow

Change History

5 versions recorded

Sep 2024 — Present [monthly]

Terminated PHASE2
Jul 2024 — Sep 2024 [monthly]

Terminated PHASE2
Jan 2021 — Jul 2024 [monthly]

Terminated PHASE2
Jun 2018 — Jan 2021 [monthly]

Terminated PHASE2
Jan 2017 — Jun 2018 [monthly]

Terminated PHASE2

First recorded

Dec 2011

Trial started

Per CT.gov start date — pre-dates our first snapshot

Eligibility Summary

No eligibility information available.

Contact Information

Sponsor contact:

Avario Healthcare Inc.
Dr. Te Vuong

Data source: Sir Mortimer B. Davis - Jewish General Hospital

For direct contact, visit the study record on ClinicalTrials.gov .

Study Locations

• Montreal, Canada